Literature DB >> 15023299

Low molecular weight heparin and atherosclerosis.

Dan Hunt1.   

Abstract

Low molecular weight heparin (LMWH) has dramatically impacted the treatment of venous thromboembolic disease and acute coronary syndromes. Recent studies help define the role of these agents for patients undergoing percutaneous coronary interventions and for patients treated with thrombolytic agents for ST-segment elevation myocardial infarction. Recent studies also suggest potential usefulness of LMWH for patients with peripheral vascular disease and its limits of utility in stroke. This review summarizes the evidence about the use of LMWH in these clinical situations.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15023299     DOI： 10.1007/s11883-004-0103-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  46 in total

Review 1.  Low-molecular-weight heparins: are they all the same?

Authors:  Richard H White; Jeffrey S Ginsberg
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

2.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Authors:  D B Mark; P A Cowper; S D Berkowitz; L Davidson-Ray; E R DeLong; A G Turpie; R M Califf; B Weatherley; M Cohen
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

Review 3.  Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction.

Authors:  James J Ferguson
Journal:  Clin Cardiol       Date:  2002-11       Impact factor: 2.882

4.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.

Authors:  L Wallentin; B Lagerqvist; S Husted; F Kontny; E Ståhle; E Swahn
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

5.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

6.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

Review 7.  The role of low-molecular-weight heparin in the management of acute coronary syndromes.

Authors:  Marc Cohen
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

8.  Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.

Authors:  S James; P Armstrong; R Califf; S Husted; F Kontny; M Niemminen; M Pfisterer; M L Simoons; L Wallentin
Journal:  Eur Heart J       Date:  2002-10       Impact factor: 29.983

9.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 10.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.